The place of targeted therapy in the patient management of non-small cell lung cancer

Lung Cancer

Volumn 57, Issue SUPPL. 2, 2007, Pages

  Thatcher, Nicholas ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Advanced non small cell lung cancer; Bevacizumab; Cetuximab; Erlotinib; Targeted therapies

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO;

ADVANCED CANCER; APOPTOSIS; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CEREBROVASCULAR DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG FATALITY; DRUG POTENTIATION; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL HEMORRHAGE; GENE DELETION; GENE MUTATION; HEADACHE; HUMAN; HYPERTENSION; HYPONATREMIA; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS CELL CARCINOMA; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PATIENT CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; SEX DIFFERENCE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; QUINAZOLINES;

EID: 34547504712     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(07)70423-3     Document Type: Article

References (21)

1. Lee C.-G., Heijn M., di tomaso E., et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60 (2000) 5565-5570
2. Inai T., Mancuso M., Hashizume H., et al. Inhibition of endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165 (2004) 35-52
3. Tong R., Boucher Y., Kozin S., Winkler F., Hicklin D., and Jain R. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64 (2004) 3731-3736
4. Graff J., McNulty A., Hanna K., et al. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65 (2005) 7462-7469
5. Sandler A., Gray R., Perry M., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006) 2542-2550
6. Sandler A., Gray R., Brahmer J., et al. Randomized phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer: An Eastern Cooperative Oncology Group Trial --E4599. J Clin Oncol 23 16S (2005) 4
7. Rosell R., Daniel C., Ramlau R., et al. RandomizedphaseII study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)expressing advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 22 14S (2004) 7012
8. West H., Franklin W., McCoy J., et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol 24 (2006) 1807-1813
9. Miller V., Hirsch F., and Johnson D. Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities. J Clin Oncol 23 (2005) 3288-3293
10. Shepherd F., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
11. Fehrenbacher L., O'Neill V., Belani C., et al. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. J Clin Oncol 24 18S (2006) 7062
12. Johnson J., Fehrenbacher, Novotny W., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. Clin Oncol 22 (2004) 2184-2191
13. Gumerlock P., Pryde B., Kimura T., et al. Enhanced cytotoxicity of docetaxel OSI-774 combination in non-small cell lung carcinoma. Proc Am Soc Clin Oncol 22 (2003) abstract 2661.
14. Kris M., Sandler A., Miller V., et al. Cigarette smoking history predicts sensitivity to erlotinib: Results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC). J Clin Oncol 22 14S (2004) 7062
15. Scagliotti G., Smit E., Boxquee L., et al. A phase II study of paclitaxel in advanced bronchioloalveolar (EORTC trial 08956). Lung Cancer 50 (2005) 91-96
16. Jackman D., Yeap B., Lindeman N., et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 25 (2007) 760-766
17. Giaccone G., Gallegos Ruiz M., Le Chevalier T., et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 12 (2006) 6049-6055
18. Lilenbaum R., Axerold R., Thomas S., et al. Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer and performance status of 2. J Clin Oncol 24 18S (2006) 7022
19. Johnson J., Cohen M., Sridhara R., et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 11 (2005) 6414-6421
20. Tsao M., Sakurada A., Cutz J., et al. Erlotinib in lung cancer --molecular and clinical predictors of outcome. N Engl J Med 353 (2005) 133-144
21. Tsao M.-S., Kamel-Reid S., and Shepherd F. Author reply to: Assessing EGFR mutations. N Engl J Med 354 (2006) 527-528